R&D On the power of T-cells, with Cedrik Britten Dr Cedrik Britten, chief medical officer at Immatics, discusses novel PRAME-directed T-cell immunotherapies.
News GSK's pullback from cell therapy continues as Immatics allia... Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up.
News GSK begins cancer cell therapy tie-up with Immatics Cancer biotech Immatics has begun a collaboration with GlaxoSmithKline to develop novel therapies built around its T-cell-based technology.
Views & Analysis European biotech round-up: Ablynx’s big break and more European biotech: a mixture of encouraging clinical trials and new funding lift the sector.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.